White Label DNA Testing: What’s Working, What’s Stalling, and Why the Gap Is Widening
The white-label genetic testing platforms gaining ground in 2026 share three characteristics: practitioner-facing reports that connect variant data to clinical decisions, data ownership agreements that hold up when patients ask hard questions, and sequencing configurations flexible enough to serve more than one clinical use case. Platforms built on consumer-grade infrastructure and reskinned for clinical use are stalling because the risk profiles are fundamentally different.